Form 4: Twist Bioscience CEO Emily Leproust Reports Gift of Shares and Stock Option Holdings
SEC Form 4 Filing
CEO Emily Leproust reported a gift of 3,000 shares to a charitable donor-advised fund and detailed her holdings of Twist Bioscience stock options.
Summary
- On May 8, 2025, Emily M. Leproust, CEO of Twist Bioscience Corp, reported a transaction involving the company's common stock.
- Leproust gifted 3,000 shares of common stock to a charitable donor-advised fund.
- Following the transaction, Leproust directly owns 652,432 shares of Twist Bioscience common stock.
- Leproust also holds multiple employee stock options with varying exercise prices and expiration dates.
- These options include 64,950 performance stock options that vested on December 19, 2022.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but the continued holding of shares and options suggests confidence in the company's future.
Positives
- The reporting person's continued service is required for the vesting of the stock options, aligning her interests with the company's long-term success.
- The vesting schedules of the options incentivize long-term commitment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the holdings and transactions of key personnel.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with shareholders, similar to practices at companies like Illumina (ILMN) and Pacific Biosciences (PACB).
- The vesting schedules of these options are typical for the biotech industry, encouraging long-term commitment, as seen in companies like CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM).
Stakeholder Impact
- The disclosure provides transparency to shareholders regarding the CEO's holdings and transactions.
- The gifting of shares may have a minor impact on the stock's float.
Key Dates
| Date | Description |
|---|---|
| 12/19/2022 | Performance stock options vested and became exercisable |
| 05/08/2025 | Date of transaction (gift of shares) |
| 05/12/2025 | Date of report |
| 09/28/2025 | Expiration date of one set of employee stock options |
| 09/28/2027 | Expiration date of one set of employee stock options |
| 11/18/2028 | Expiration date of one set of employee stock options |
| 10/23/2029 | Expiration date of one set of employee stock options |
| 08/31/2030 | Expiration date of one set of employee stock options |
Keywords
Twist Bioscience, CEO, Emily Leproust, Stock Options, Beneficial Ownership, Form 4, Gift, Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.